GLEIF logo

GLEIF-accredited LEI Issuer. #1 LEI Issuer Globally.

RapidLEI logo

Public LEI record · Global LEI Index Managed by RapidLEI

Austria

Erste Pharmaceuticals GmbH

Neuwaldegger Straße 4a/2/1, Wien, 1170, AT

Legal Entity Identifier 9845003F4EB4777E8227
Entity status
Active
LEI status
Issued
Policy conformity
Conforming
Reference data
Register-verified
Next renewal
15 Jul 2027
LEI Issuer
Ubisecure RapidLEI Get a signed certificate

Record snapshot

The Legal Entity Identifier for Erste Pharmaceuticals GmbH is 9845003F4EB4777E8227. It is valid, policy conforming and renewed until 15 Jul 2027.

Erste Pharmaceuticals GmbH is a Gesellschaft mit beschränkter Haftung formed in Austria, registered as 506562w with Commercial Register, Austria. The LEI was registered on 15 Jul 2021 and has been renewed 5 times since. At its last validation on 16 May 2026, all of its Level 1 reference data was confirmed against Commercial Register, Austria. It reports no parent, on the grounds that it is controlled by individuals, who cannot hold an LEI. RapidLEI maintains the record.

268 Days left in this cycle

Record lifecycle

Five successful renewals, no break in 5 years.

First LEI registered on 15 Jul 2021 and has been maintained for 5 years with 5 renewals recorded. The next renewal falls due on 15 Jul 2027, which is 9 months from today.

15 Jul 2021 LEI issued Five renewal marks Each mark is a renewal that completed 15 Jul 2027 Next renewal due

Registered entity Level 1 data

Legal name
Erste Pharmaceuticals GmbHRegistered in German
Legal form
Gesellschaft mit beschränkter Haftung AXSB
Jurisdiction
Austria AT
Registration
Registered at Commercial Register, Austria RA000017. Registration number 506562w
Entity created
17 Jan 2019
Legal address
Neuwaldegger Straße 4a/2/1, Wien, 1170, AT
Connected identifiers
QCCQAT6R3PWRV S&P Capital IQ1675168491 Other identifiers recorded against this LEI.
Securities
Not recorded No ISIN is mapped to this LEI in the ANNA and GLEIF ISIN-to-LEI file. That records the absence of a mapping, not the absence of securities.

What this record’s status means

Reference data
Register-verified GLEIF records this as fully corroborated. At its last validation, all of the entity's Level 1 reference data was verified against an authoritative public source.

Changes to this record

  1. Renewed. The next renewal date moved from 15 Jul 2026 to 15 Jul 2027.

Show 7 earlier changes

  1. Renewed. The next renewal date moved from 15 Jul 2025 to 15 Jul 2026.

  2. Renewed. The next renewal date moved from 15 Jul 2024 to 15 Jul 2025.

  3. A legal address was recorded.

  4. A headquarters address was recorded.

  5. Renewed. The next renewal date moved from 15 Jul 2023 to 15 Jul 2024.

  6. Renewed. The next renewal date moved from 15 Jul 2022 to 15 Jul 2023.

  7. The LEI was registered and first published to the Global LEI Index.

Ownership Level 2 data

  1. Ultimate parent
    Owned by individuals Reported exception Natural persons cannot hold an LEI
  2. Direct parent
    Owned by individuals Reported exception Natural persons cannot hold an LEI
  3. This entity

    Erste Pharmaceuticals GmbH

    AT · 9845003F4EB4777E8227

    Active

  4. Below
    0 Direct subsidiaries
    0 Ultimate subsidiaries

    The chain ends here. No other entity reports Erste Pharmaceuticals GmbH as its parent, so the count is a stated zero rather than data still to arrive.

Level 2 data records who consolidates this entity. A reported relationship, or a reported reason for the absence of one, both satisfy the standard. Only a record carrying neither is incomplete.

Where this data comes from

Source registry

Commercial Register, Austria

Validated against

Commercial Register, Austria

Maintained by

Ubisecure RapidLEI

Published in

The GLEIF Global LEI Index. This record last updated 16 May 2026

Erste Pharmaceuticals GmbH

Add this schema to your homepage. Replace the two example.com values with your own homepage address before publishing.

How to use this

Reference data from the GLEIF Global LEI Index, as published on 16 May 2026.